New phase 2 results from the RC48G001 trial showed disitamab vedotin (DV), a HER2‑targeted ADC with an MMAE payload, produced confirmed overall response rates of 54.9% in HER2‑positive and 52.6% in HER2‑low metastatic urothelial carcinoma. Median progression‑free survival was 5.7 months in both cohorts and median overall survival ranged near 17–20 months. Data were presented at the ASCO Genitourinary Cancers Symposium and experts including Jun Gong noted DV’s different payload and mechanism compared with trastuzumab deruxtecan. The findings extend interest in HER2‑directed ADCs for bladder cancer across HER2 expression levels and support continued global development.